$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000100069423000055 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$291.3M	$187.0M	$734.6M
YoY Change	-18.48%	-74.55%	310.74%
Cost Of Revenue	$155.0M	$98.93M	$434.6M
YoY Change	-14.74%	-77.24%
Gross Profit	$136.4M	$88.06M	$300.0M
YoY Change	-22.36%	-70.65%	67.74%
Gross Profit Margin	46.81%	47.09%	40.84%
Selling, General & Admin	$155.2M	$107.5M	$122.9M
YoY Change	-3.97%	-12.51%	57.95%
% of Gross Profit	113.84%	122.08%	40.96%
Research & Development	$164.7M	$106.2M	$304.3M
YoY Change	-36.13%	-65.09%	-25.45%
% of Gross Profit	120.78%	120.64%	101.44%
Depreciation & Amortization	$10.79M	$11.30M	$8.347M
YoY Change	49.46%	35.38%	95.85%
% of Gross Profit	7.92%	12.83%	2.78%
Operating Expenses	$319.9M	$106.2M	$304.3M
YoY Change	-23.74%	-65.09%	-25.45%
Operating Profit	-$183.6M	-$125.6M	-$127.2M
YoY Change	-24.73%	-1.22%	-58.59%
Interest Expense	-$4.117M	$2.859M	$4.169M
YoY Change	-10.52%	-31.42%	-19.55%
% of Operating Profit
Other Income/Expense, Net	$10.98M	-$2.982M	-$34.78M
YoY Change	-82.83%	-91.43%	691.6%
Pretax Income	-$176.7M	-$131.5M	-$166.1M
YoY Change	-4.23%	-20.87%	-47.49%
Income Tax	$1.688M	-$697.0K	$2.472M
% Of Pretax Income
Net Earnings	-$178.4M	-$130.8M	-$168.6M
YoY Change	-2.12%	-22.44%	-47.71%
Net Earnings / Revenue	-61.23%	-69.94%	-22.95%
Basic Earnings Per Share		-$1.26	-$2.15
Diluted Earnings Per Share	-$1.44	-$1.26	-$2.154M
COMMON SHARES
Basic Shares Outstanding	118.8M shares	94.40M shares	78.22M shares
Diluted Shares Outstanding		103.4M shares	78.27M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$568.5M	$651.1M	$1.281B
YoY Change	-57.48%	-49.16%	-33.89%
Cash & Equivalents	$568.5M	$651.1M	$1.281B
Short-Term Investments
Other Short-Term Assets	$155.7M	$162.4M	$285.3M
YoY Change	103.9%	-43.08%	124.26%
Inventory	$41.70M	$69.59M	$82.43M
Prepaid Expenses
Receivables	$297.2M	$123.7M	$111.6M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.144B	$1.007B	$1.760B
YoY Change	-32.85%	-42.8%	-19.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$305.8M	$301.0M	$255.5M
YoY Change	3.92%	17.79%	18.99%
Goodwill	$127.5M	$123.8M	$117.5M
YoY Change	0.89%	5.31%	-10.95%
Intangibles			$8.456M
YoY Change			68.21%
Long-Term Investments
YoY Change
Other Assets	$35.16M	$34.89M	$17.41M
YoY Change	23.5%	100.45%	-54.6%
Total Long-Term Assets	$653.6M	$650.4M	$507.5M
YoY Change	17.71%	28.16%	29.54%
TOTAL ASSETS
Total Short-Term Assets	$1.144B	$1.007B	$1.760B
Total Long-Term Assets	$653.6M	$650.4M	$507.5M
Total Assets	$1.797B	$1.657B	$2.267B
YoY Change	-20.42%	-26.91%	-11.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$132.6M	$101.9M	$145.0M
YoY Change	-38.75%	-29.71%	143.43%
Accrued Expenses	$394.7M	$311.2M	$551.1M
YoY Change	-33.24%	-43.53%	70.15%
Deferred Revenue	$241.3M	$192.2M	$404.8M
YoY Change	-39.68%	-52.52%
Short-Term Debt	$0.00	$0.00	$324.5M
YoY Change		-100.0%
Long-Term Debt Due	$5.142M	$1.300M	$82.10M
YoY Change	-98.54%	-98.42%	-21.05%
Total Short-Term Liabilities	$1.635B	$1.469B	$1.668B
YoY Change	-33.53%	-11.95%	-4.87%
LONG-TERM LIABILITIES
Long-Term Debt	$223.9M	$220.8M	$31.47M
YoY Change	13.27%	601.53%	-90.26%
Other Long-Term Liabilities	$33.13M	$37.30M	$98.57M
YoY Change	-40.52%	-62.16%	250.93%
Total Long-Term Liabilities	$33.13M	$37.30M	$98.57M
YoY Change	-40.52%	-62.16%	250.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.635B	$1.469B	$1.668B
Total Long-Term Liabilities	$33.13M	$37.30M	$98.57M
Total Liabilities	$2.514B	$2.336B	$2.833B
YoY Change	-13.08%	-17.57%	34.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.821B	-$4.643B	-$4.094B
YoY Change	12.75%	13.41%	47.7%
Common Stock	$1.405M	$1.196M	$792.0K
YoY Change	61.87%	51.01%	4.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$89.94M
YoY Change			13.66%
Treasury Stock Shares			727.7K shares
Shareholders Equity	-$716.9M	-$678.4M	-$566.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.797B	$1.657B	$2.267B
YoY Change	-20.42%	-26.91%	-11.63%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$178.4M	-$130.8M	-$168.6M
YoY Change	-2.12%	-22.44%	-47.71%
Depreciation, Depletion And Amortization	$10.79M	$11.30M	$8.347M
YoY Change	49.46%	35.38%	95.85%
Cash From Operating Activities	-$176.8M	-$39.70M	-$38.71M
YoY Change	50.05%	2.56%	-72.77%
INVESTING ACTIVITIES
Capital Expenditures	$8.839M	$18.10M	-$29.52M
YoY Change	-59.94%	-161.32%	142.16%
Acquisitions
YoY Change
Other Investing Activities	-$239.0K	-$200.0K	$0.00
YoY Change
Cash From Investing Activities	-$9.078M	-$18.40M	-$29.52M
YoY Change	-58.86%	-37.67%	142.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	100.4M	197.1M	-30.98M
YoY Change	-47.56%	-736.3%	97.05%
NET CHANGE
Cash From Operating Activities	-176.8M	-39.70M	-38.71M
Cash From Investing Activities	-9.078M	-18.40M	-29.52M
Cash From Financing Activities	100.4M	197.1M	-30.98M
Net Change In Cash	-85.47M	139.0M	-99.20M
YoY Change	-265.77%	-240.12%	-41.66%
FREE CASH FLOW
Cash From Operating Activities	-$176.8M	-$39.70M	-$38.71M
Capital Expenditures	$8.839M	$18.10M	-$29.52M
Free Cash Flow	-$185.6M	-$57.80M	-$9.189M
YoY Change	32.7%	529.01%	-92.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1700000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	19000000	usd
	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	300000	usd
	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	4300000	usd
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2300000	usd
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
	us-gaap	Severance Costs1 SeveranceCosts1	4503000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10081000	usd
	us-gaap	Restructuring Charges RestructuringCharges	14584000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	2859000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	4169000	usd
	us-gaap	Interest Expense InterestExpense	10299000	usd
	us-gaap	Interest Expense InterestExpense	15279000	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.26
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.94
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.13
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103429000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93046000	shares
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3686000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-12924000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-5486000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-22441000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3686000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-12924000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5486000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22441000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-134462000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-181537000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-372159000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	651104000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1336883000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10393000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10303000	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	123657000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	82375000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	69592000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	36683000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	152018000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	237147000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1006764000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1703391000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	300982000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	294247000	usd
CY2023Q3	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	190741000	usd
CY2022Q4	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	106241000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	123780000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	126331000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34890000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28469000	usd
CY2023Q3	us-gaap	Assets Assets	1657157000	usd
CY2022Q4	us-gaap	Assets Assets	2258679000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	101914000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	216517000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	311201000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	591158000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	192187000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	370137000	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1332000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27196000	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	324881000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	861956000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	930055000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1468590000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2459944000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	608842000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	179414000	usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	167621000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	166466000	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	53158000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	31238000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37296000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	55695000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2335507000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2892757000	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86806554	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86039923	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	1196000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	868000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4066585000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3737979000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4642562000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4275889000	usd
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	911269	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	766631	shares
CY2023Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	91706000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	90659000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11863000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6377000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-678350000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-634078000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1657157000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2258679000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-754519000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21254000	usd
CY2023Q3	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	354000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3063000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	189023000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-416950000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33386000	usd
CY2022Q3	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	-884000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-12924000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-168613000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-565985000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-634078000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	70193000	usd
	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	699000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3924000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	256995000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-5486000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-678350000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-351673000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	104367000	usd
	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	67000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2311000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	179385000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-22441000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-475690000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-565985000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-475690000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	30431000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21832000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	69699000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	102525000	usd
	nvax	Provision For Excess And Obsolete Inventory ProvisionForExcessAndObsoleteInventory	49533000	usd
	nvax	Provision For Excess And Obsolete Inventory ProvisionForExcessAndObsoleteInventory	358075000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10081000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	0	usd
	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	40187000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3015000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	25059000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	82542000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	426466000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	34418000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-171325000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-349261000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	90418000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	138979000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-155268000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-537186000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-298121000	usd
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	44932000	usd
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	66033000	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	4796000	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	4888000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49728000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70921000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	256995000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	179385000	usd
	nvax	Net Proceeds From The Exercise Of Stock Based Awards NetProceedsFromTheExerciseOfStockBasedAwards	699000	usd
	nvax	Net Proceeds From The Exercise Of Stock Based Awards NetProceedsFromTheExerciseOfStockBasedAwards	67000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	25026000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	45904000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	325000000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3591000	usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-95923000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	133548000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	355000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	257000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-682482000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-235237000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1348845000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1528259000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	666363000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1293022000	usd
	nvax	Non Cash Related Transactions For Finance Lease Right Of Use Asset NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset	96492000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2394000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11984000	usd
	nvax	Internal Use Software Included In Accounts Payable And Accrued Expenses InternalUseSoftwareIncludedInAccountsPayableAndAccruedExpenses	167000	usd
	nvax	Internal Use Software Included In Accounts Payable And Accrued Expenses InternalUseSoftwareIncludedInAccountsPayableAndAccruedExpenses	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	17260000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-11900000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-6400000	usd
CY2023Q3	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	-12200000	usd
	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	3900000	usd
CY2022Q3	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	-38600000	usd
	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	-59600000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	666400000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-366700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-537200000	usd
	nvax	Number Of Population Members NumberOfPopulationMembers	1000000	member
CY2023Q2	nvax	Restructuring And Related Cost Number Of Positions Eliminated Global Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent	0.25
CY2023Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.20
	us-gaap	Severance Costs1 SeveranceCosts1	4500000	usd
CY2023Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10100000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	549551000	usd
	nvax	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	422766000	usd
	nvax	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	171288000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	801029000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div>
CY2023Q3	us-gaap	Billed Contract Receivables BilledContractReceivables	71100000	usd
CY2022Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	53800000	usd
CY2023Q3	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	52600000	usd
CY2022Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	28600000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	96210000	usd
	nvax	Accounts Receivable Before Allowance For Credit Loss Additions AccountsReceivableBeforeAllowanceForCreditLossAdditions	981305000	usd
	nvax	Accounts Receivable Before Allowance For Credit Loss Deductions AccountsReceivableBeforeAllowanceForCreditLossDeductions	946182000	usd
CY2023Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	131333000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	454993000	usd
	nvax	Accounts Receivable Before Allowance For Credit Loss Additions AccountsReceivableBeforeAllowanceForCreditLossAdditions	1519345000	usd
	nvax	Accounts Receivable Before Allowance For Credit Loss Deductions AccountsReceivableBeforeAllowanceForCreditLossDeductions	1862693000	usd
CY2022Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	111645000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	13835000	usd
	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
	nvax	Accounts Receivable Allowance For Credit Loss Deductions AccountsReceivableAllowanceForCreditLossDeductions	-6159000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7676000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
	nvax	Accounts Receivable Allowance For Credit Loss Deductions AccountsReceivableAllowanceForCreditLossDeductions	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1595472000	usd
	nvax	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	96298000	usd
	nvax	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	251576000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1440194000	usd
	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
CY2023Q3	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
CY2022Q3	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	0	usd
	nvax	Accounts Receivable Allowance For Credit Loss Deductions AccountsReceivableAllowanceForCreditLossDeductions	-6200000	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2000000000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	801000000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-64700000	usd
	nvax	Royalty Period RoyaltyPeriod	P15Y
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	651104000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1336883000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10393000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10303000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4866000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1659000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	666363000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1348845000	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	10385000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	13912000	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	10405000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	21410000	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	48802000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1361000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	69592000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	36683000	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	18100000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	49600000	usd
CY2023Q3	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	63500000	usd
	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	71900000	usd
CY2023Q3	nvax	Inventory Firm Purchase Commitment Recoveries InventoryFirmPurchaseCommitmentRecoveries	21500000	usd
	nvax	Inventory Firm Purchase Commitment Recoveries InventoryFirmPurchaseCommitmentRecoveries	40300000	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	202400000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	358100000	usd
CY2022Q3	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	46600000	usd
	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	146200000	usd
CY2022	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2022Q4	us-gaap	Goodwill Goodwill	126331000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-2551000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	123780000	usd
CY2023Q3	nvax	Short Term Lease Cost Benefit ShortTermLeaseCostBenefit	-39500000	usd
	nvax	Short Term Lease Cost Benefit ShortTermLeaseCostBenefit	-48000000	usd
CY2022Q3	nvax	Short Term Lease Cost Benefit ShortTermLeaseCostBenefit	-46600000	usd
	nvax	Short Term Lease Cost Benefit ShortTermLeaseCostBenefit	37300000	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	24200000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	44000000	usd
CY2023Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	500000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1400000	usd
CY2022Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	900000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4300000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	5900000	usd
CY2023Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	0	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	119000	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	324881000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	7629000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	8784000	usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	167621000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	166466000	usd
CY2023Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	2191000	usd
CY2022Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3047000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	7588000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9141000	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	395000	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	356000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1295000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1068000	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	2586000	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	3403000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	8883000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	10209000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20760000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31547000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	69699000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	102525000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	500000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	500000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1700000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	102000000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3000000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1400000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2022Q1	us-gaap	Capitalized Contract Cost Amortization Period CapitalizedContractCostAmortizationPeriod	P15Y
CY2023Q3	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	-700000	usd
CY2022Q3	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	2400000	usd
CY2022Q3	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	100000	usd
CY2023Q3	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Loss Contingency Number Of Defendants LossContingencyNumberOfDefendants	2	defendant
CY2022Q4	nvax	Loss Contingency Period To Answer LossContingencyPeriodToAnswer	P14D
CY2022Q4	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	8	lawsuit
	nvax	Payments For Severance And Employee Benefit Costs PaymentsForSeveranceAndEmployeeBenefitCosts	4300000	usd
CY2023Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10100000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	5900000	usd
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
nvax-20230930_cal.xml	Edgar Link	unprocessable
0001000694-23-000055-index-headers.html	Edgar Link	pending
0001000694-23-000055-index.html	Edgar Link	pending
0001000694-23-000055.txt	Edgar Link	pending
0001000694-23-000055-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nvax-20230930_def.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvax-20230930.htm	Edgar Link	pending
nvax-20230930.xsd	Edgar Link	pending
nvax-20230930xex101.htm	Edgar Link	pending
nvax-20230930xex311.htm	Edgar Link	pending
nvax-20230930xex312.htm	Edgar Link	pending
nvax-20230930xex321.htm	Edgar Link	pending
nvax-20230930xex322.htm	Edgar Link	pending
nvax-20230930_g1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
nvax-20230930_lab.xml	Edgar Link	unprocessable
nvax-20230930_pre.xml	Edgar Link	unprocessable
nvax-20230930_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2023 Q4 Form 10-Q Financial Statement

#000100069423000055 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2023 Q4 Form 10-Q Financial Statement

#000100069423000055 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax